Join
Live feed
·
PRReleasevia Quantisnow
Celcuity Inc. logo

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

ByQuantisnow·Wall Street's wire, on your screen.
CELC· Celcuity Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CELC (Celcuity Inc.) and more on Quantisnow.